TENAX THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
TENAX THERAPEUTICS, INC. (TENX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 4 shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-03-10
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 1.00 shares.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 0.00 shares.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2016-06-30 was 156.65K shares, a 24000.62% increase year-over-year.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2016-03-31 was 0.00 shares.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 4.00 shares, a 0.00% change from fiscal 2024.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 4.00 shares, a 87.88% decline from fiscal 2023.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 33.00 shares.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2014 was 1.30K shares, a 83.44% decline from fiscal 2013.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 1.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 1.00 shares derived: sum of 2 quarters · filed 2026-03-10 | 4.00 shares 10-K · filed 2026-03-10 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 3.00 shares 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | 3.00 shares 10-Q · filed 2025-08-13 | |||
| 2024-12-31 | 4.00 shares 10-K · filed 2026-03-10 | |||
| 2023-12-31 | 33.00 shares 10-K · filed 2025-03-25 | |||
| 2016-06-30 | 156.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | 156.65K shares 10-Q · filed 2016-08-09 | ||
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-10 | |||
| 2015-10-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-12-10 | 650.00 shares 10-Q · filed 2015-12-10 | ||
| 2015-07-31 | 650.00 shares 10-Q · filed 2015-09-09 | |||
| 2015-01-31 | 1.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-03-17 | 8.30K shares derived: sum of 2 quarters · filed 2015-03-17 | 4.68K shares 10-Q · filed 2015-03-17 | 5.43K shares derived: sum of 4 quarters · filed 2015-03-17 |
| 2014-10-31 | 7.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-12-15 | 3.63K shares 10-Q · filed 2014-12-15 | 4.38K shares derived: sum of 3 quarters · filed 2014-12-15 | 4.38K shares derived: sum of 4 quarters · filed 2014-12-15 |
| 2014-07-31 | -3.63K shares 10-Q · filed 2014-09-15 | -2.88K shares derived: sum of 2 quarters · filed 2014-09-15 | -2.88K shares derived: sum of 3 quarters · filed 2014-09-15 | |
| 2014-04-30 | 750.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-07-29 | 750.00 shares derived: sum of 2 quarters · filed 2014-07-29 | 1.30K shares 10-K · filed 2014-07-29 | |
| 2014-01-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-03-17 | 550.00 shares 10-Q · filed 2014-03-17 | ||
| 2013-10-31 | 550.00 shares 10-Q · filed 2013-12-17 | |||
| 2013-04-30 | -144.15K shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-07-29 | -96.82K shares derived: sum of 2 quarters · filed 2014-07-29 | 3.13K shares derived: sum of 3 quarters · filed 2014-07-29 | 7.85K shares 10-K · filed 2014-07-29 |
| 2013-01-31 | 47.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-03-18 | 147.28K shares derived: sum of 2 quarters · filed 2013-03-18 | 152.00K shares 10-Q · filed 2013-03-18 | |
| 2012-10-31 | 99.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2012-12-14 | 104.67K shares 10-Q · filed 2012-12-14 | ||
| 2012-07-31 | 4.72K shares 10-Q · filed 2012-09-19 | |||
| 2012-04-30 | 13.16K shares 10-K · filed 2013-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |